$ARMP Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis
[Float 9.73M] [Short 0.24%]
$JFBR W Jeffs' Brands to Acquire [Amazon.uk]( Market Leader in the $2 Billion Market of Pest Control Products for $1.9 million
[Float 2.10M] [Short 8.58%]
$VRAX EXCLUSIVE: Virax Biolabs Tells . It Has Entered An Agreement For Distribution Of An Avian Influenza A Virus Real-Time PCR Test Kit To Markets Accepting The CE Mark $QQQ [Float 5.80M] [Short 2.02%]
$CFRX Contrafect has received a decision to grant European patent number EP3685851 titled "BACTERIOPHAGE LYSIN AND ANTIBIOTIC COMBINATIONS AGAINST GRAM POSITIVE BACTERIA". [Float 0.47M] [Short 11.20%]
$TRVI Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
[Float 57.54M] [Short 0.14%]
$RNXT RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer
[Float 7.29M] [Short 0.33%]
$HSDT Helius Medical Technologies Announces Authorization from Health Canada to Market Portable Neuromodulation Stimulator (PoNS®) Device for the Treatment of Gait Deficit Due to Mild and Moderate Symptoms from Strok
[Float 27.88M] [Short
$PPIH Perma-Pipe International Holdings Inc. announces Approval of Joint Venture by The Kingdom of Saudi Arabia General Authority for Competition
[Float 7.55M] [Short 0.01%]
$ATXI AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease
[Float 4.20M] [Short 3.92%]
$PTN Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
$RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients